Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Subgroup Analysis of Quality-of-Life Outcomes in Patients Achieving F-VASI75: Pooled Results from Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo

Speaker(s)

Pandya AG1, van Geel N2, Butler K3, Bibeau K3, Gao J3, Ezzedine K4
1Palo Alto Foundation Medical Group, Mountain View, CA, USA, and University of Texas Southwestern Medical Center, Dallas, TX, USA, 2Ghent University Hospital, Ghent, PA, Belgium, 3Incyte Corporation, Wilmington, DE, USA, 4Henri Mondor University Hospital and Université Paris-Est Créteil Val de Marne, Paris, France

Presentation Documents

Objectives

Vitiligo is a chronic autoimmune skin disease associated with quality-of-life (QoL) burden. Ruxolitinib (Janus kinase [JAK] 1/JAK2 inhibitor) cream demonstrated clinically meaningful repigmentation and was generally well tolerated in the 52-week TRuE-V1/TRuE-V2 phase 3 vitiligo studies. Pooled interim subgroup analyses of QoL outcomes are reported in patients who achieved the primary endpoint of ≥75% improvement in facial Vitiligo Area Scoring Index (F-VASI75), since QoL improvements often require a high degree of repigmentation in vitiligo.

Methods

Patients ≥12 years old with nonsegmental vitiligo and depigmentation covering ≤10% total body surface area (BSA) were randomized 2:1 to twice-daily 1.5% ruxolitinib cream or vehicle for 24 weeks. QoL measures included the Dermatology Life Quality Index (DLQI) and Vitiligo-specific QoL (VitiQoL), with higher scores indicating worse QoL.

Results

TRuE-V1/TRuE-V2 randomized 674 patients (ruxolitinib cream, n=450; vehicle, n=224). Mean (SD) age was 39.6 (15.1) years. Mean (SD) facial and total BSA at baseline was 1.02% (0.64) and 7.39% (2.03), respectively. At Week 24, F-VASI75 was achieved by 30.1% of patients who applied ruxolitinib cream vs 10.8% who applied vehicle (P<0.0001). Among patients who achieved F-VASI75, there were no significant differences in the change from baseline in total scores on the DLQI or VitiQoL at Weeks 12 or 24 for ruxolitinib cream vs vehicle (all P>0.05). However, QoL appeared to improve from Weeks 12 to 24 per the least squares mean change from baseline (SE) in DLQI (–1.3 [0.3] to –1.9 [0.4]) and VitiQoL (–6.3 [1.4] to –9.2 [1.5]) among patients who applied ruxolitinib cream.

Conclusions

Although application of ruxolitinib cream was not associated with improved QoL vs vehicle at Week 24, there were trends for improvement in both the DLQI and VitiQoL among patients who achieved the primary endpoint of F-VASI75.

Code

CO130

Topic

Clinical Outcomes, Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes, Performance-based Outcomes

Disease

No Additional Disease & Conditions/Specialized Treatment Areas